Results 1 to 10 of about 23,474 (264)

Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma [PDF]

Cancers, 2021
Direct intralesional injection of specific or even generic agents, has been proposed over the years as cancer immunotherapy, in order to treat cutaneous or subcutaneous metastasis. Such treatments usually induce an effective control of disease in injected lesions, but only occasionally were able to demonstrate a systemic abscopal effect on distant ...
Pier Francesco Ferrucci, Laura Pala, Fabio Conforti   +2 more
exaly   +5 more sources

Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy [PDF]

Journal of Clinical Medicine, 2023
The landscape of melanoma treatment has undergone a dramatic revolution in the past decade. The use of oncolytic viruses (OVs) represents a novel therapeutic approach that can selectively infect and lyse tumor cells and induce local and systemic antitumor immune responses.
Jian Ye
exaly   +4 more sources

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells [PDF]

Frontiers in Immunology, 2021
T-VEC, a HSV-1 derived oncolytic virus, is approved for the treatment of advanced melanoma. The mechanisms that underly the systemic anti-tumor effect that is seen following intratumoral injection have not yet been studied but are likely to be mediated ...
Jens Tijtgat, Jolien De Munck, Inès Dufait, Julia Katharina Schwarze, Ivan Van Riet, Lorenzo Franceschini, Karine Breckpot, Joeri L. Aerts, Bart Neyns, Sandra Tuyaerts   +9 more
doaj   +7 more sources

Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Melanoma [PDF]

Immunotherapy, 2015
Melanoma often spreads to cutaneous or subcutaneous sites that are amenable to direct, intralesional injection. As such, developing effective injectable agents has been of considerable interest. Talimogene laherperepvec (T-VEC) is an injectable modified oncolytic herpes virus being developed for the treatment of advanced melanoma.
Douglas B Johnson, Msci, Igor Puzanov
exaly   +5 more sources

Successful treatment of in-transit metastatic melanoma with combination intralesional T-VEC and topical imiquimod immunotherapy [PDF]

Journal for ImmunoTherapy of Cancer
In-transit metastases of malignant melanoma pose a significant clinical challenge, particularly in patients with contraindications to systemic therapies. While surgical excision and systemic immunotherapies remain standard treatments, localized therapies
Jeffrey Sosman, Sunandana Chandra, Danielle Lam, Jennifer Choi, Marisa Lenga, Esther Choi, Kirsten Johnson, Lauren Schiemann   +7 more
doaj   +4 more sources

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy [PDF]

Journal for ImmunoTherapy of Cancer, 2016
With the recent regulatory approval of Talimogene laherparepvec (T-VEC) for the treatment of advanced of melanoma in the United States, Europe and Australia, oncolytic virus immunotherapy has earned its place in the clinic. However, the adoption of T-VEC
Ann W. Silk, Howard L. Kaufman, Hasan Rehman, Michael P. Kane   +3 more
doaj   +5 more sources

Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T‐VEC) a first‐in‐class oncolytic viral therapy in patients with advanced melanoma [PDF]

CPT: Pharmacometrics & Systems Pharmacology, 2023
Talimogene Laherparepvec (T‐VEC) is a first‐in‐class oncolytic virotherapy approved for the treatment of unresectable melanoma recurrent after initial surgery.
Malidi Ahamadi, Johannes Kast, Po‐Wei Chen, Xiaojun Huang, Sandeep Dutta, Vijay V. Upreti   +5 more
doaj   +2 more sources

False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T-VEC). [PDF]

J Surg Oncol, 2021
AbstractTalimogene laherparepvec (T‐VEC) is a genetically modified herpes simplex virus‐1‐based oncolytic immunotherapy and has been approved for the local treatment of unresectable (stage IIIB/C and IVM1a) cutaneous melanoma. During T‐VEC treatment, tumor response is often evaluated using [18F]2‐fluoro‐2‐deoxy‐ d‐glucose(FDG) positron emission ...
Mulder EEAP, Stahlie EHA, Verver D, Lemstra C, Been LB, Mooyaart AL, Brabander T, Vegt E, Verburg FA, van der Veldt AAM, Verhoef C, van Akkooi ACJ, Grünhagen DJ.   +12 more
europepmc   +8 more sources

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial [PDF]

BMC Cancer, 2022
Background Trials investigating neoadjuvant treatment with immune checkpoint inhibitors (ICI) in patients with melanoma have shown high clinical and pathologic response rates.
Maartje W. Rohaan, Emma H. A. Stahlie, Viola Franke, Lisanne P. Zijlker, Sofie Wilgenhof, Vincent van der Noort, Alexander C. J. van Akkooi, John B. A. G. Haanen   +7 more
doaj   +2 more sources

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany [PDF]

Journal for ImmunoTherapy of Cancer, 2021
Background Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe.
Erika Richtig, Joanna Mangana, Christian Posch, Christoph Hoeller, Julia Maria Ressler, Matthias Karasek, Lukas Koch, Rita Silmbrod, Veronica Aedo-Lopez, Helmut Kehrer, Felix Weihsengruber, Peter Koelblinger, Julian Kofler, Christine Hafner   +13 more
doaj   +2 more sources